Eagle gets CRL for Ryanodex

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) lost $16.67 (24%) to $53.37 on Wednesday after it said FDA issued a complete response letter for Ryanodex dantrolene to treat exertional heat stroke.

The company said FDA has requested an additional clinical trial in the indication, and said it is considering its options...